Who we are

A New Class Of Immunotherapeutic Drugs

Orion Biotechnology is a clinical stage biopharmaceutical company focused on discovering and developing best-in-class immunotherapeutics based on novel recombinant chemokine analogs.   Our goal is to significantly improve the health outcomes of populations affected by serious diseases in the area of oncology, neuroinflammatory disorders, inflammatory bowel disease, HIV, and others.  By utilizing our proprietary Drug Discovery Platform we will be able to accelerate the identification and lead optimization of chemokine analogs and other small proteins.   Our first biologic – OB-002 – is being targeted at critical unmet needs with indications in Oncology, Multiple Sclerosis and is currently in clinical trials for HIV prevention.

Management

Mark Groper

Mark Groper

Mark Groper

Mark Groper

Mark Groper

Mark Groper